Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Map2k6 is a potent genetic modifier of arterial rupture in vascular Ehlers-Danlos syndrome mice
Caitlin J. Bowen, Rebecca Sorber, Juan Francisco Calderón Giadrosic, Jefferson J. Doyle, Graham Rykiel, Zachary Burger, Xiaoyan Zhang, Wendy A. Espinoza Camejo, Nicole Anderson, Simone Sabnis, Chiara Bellini, Elena Gallo MacFarlane, Harry C. Dietz
Caitlin J. Bowen, Rebecca Sorber, Juan Francisco Calderón Giadrosic, Jefferson J. Doyle, Graham Rykiel, Zachary Burger, Xiaoyan Zhang, Wendy A. Espinoza Camejo, Nicole Anderson, Simone Sabnis, Chiara Bellini, Elena Gallo MacFarlane, Harry C. Dietz
View: Text | PDF
Research Article Cardiology Genetics Vascular biology

Map2k6 is a potent genetic modifier of arterial rupture in vascular Ehlers-Danlos syndrome mice

  • Text
  • PDF
Abstract

Aortic dissection or rupture is a major cause of mortality in vascular Ehlers-Danlos syndrome (vEDS), a connective tissue disorder caused by heterozygous mutations in the collagen type III alpha 1 chain (COL3A1) gene. C57BL6/J (BL6) mice carrying the Col3a1G938D/+ mutation recapitulate the vEDS vascular phenotype and die suddenly of aortic rupture/dissection. However, 129S6/SvEvTac (referred to here as 129) mice expressing the same Col3a1G938D/+ mutation show near-complete lifelong protection from vascular rupture. To identify genetic modifiers of vascular risk in vEDS, we performed genome-wide genotyping of intercrossed BL6/129 vEDS mice stratified by survival and identified a significant protective locus encompassing a variant in Map2k6, encoding mitogen-activated protein kinase kinase 6 (M2K6), a p38-activating kinase. Genetic ablation of Map2k6 rendered previously protected 129 vEDS mice susceptible to aortic rupture, in association with reduced protein phosphatase 1 activity and increased PKC and ERK phosphorylation. Accelerated vascular rupture in vEDS mice treated with a pharmacological inhibitor of p38 was rescued by concomitant ERK antagonism, supporting an opposing role for ERK and p38 in the modification of aortic rupture risk in vEDS. These results suggest that pharmacologic strategies aimed at mimicking the effect of this natural protective pathway may attenuate aortic rupture risk in vEDS.

Authors

Caitlin J. Bowen, Rebecca Sorber, Juan Francisco Calderón Giadrosic, Jefferson J. Doyle, Graham Rykiel, Zachary Burger, Xiaoyan Zhang, Wendy A. Espinoza Camejo, Nicole Anderson, Simone Sabnis, Chiara Bellini, Elena Gallo MacFarlane, Harry C. Dietz

×

Figure 3

Map2k6 exerts a protective effect against death by aortic rupture in vEDS mice.

Options: View larger image (or click on image) Download as PowerPoint
Map2k6 exerts a protective effect against death by aortic rupture in vED...
Kaplan-Meier survival curve comparing (A) male 129 vEDS Map2k6+/+ (n = 17), vEDS Map2k6+/– (n = 20), and vEDS Map2k6–/– mice (n = 10) and (B) female 129 vEDS Map2k6+/+ (n = 19), vEDS Map2k6+/– (n = 15), and vEDS Map2k6–/– mice (n = 12). Significant differences were calculated using log-rank (Mantel-Cox) analysis (* P < 0.05; ** P < 0.01). (C) Immunoblot analysis of phosphorylated PKC at residue Ser660 (pPKC) and phosphorylated ERK (pERK1/2) comparing aortic lysates obtained from the proximal descending aortas of mice at 2 months of age. (D) Quantification of p-PKC and p-ERK normalized to β-actin of control Map2k6+/+ (n = 3), vEDS Map2k6+/+ (n = 4), control Map2k6–/– (n = 7), and vEDS Map2k6–/– (n = 5) mice. P value refers to 2-way ANOVA with Holm-Šídák post hoc test (* P < 0.05, *** P < 0.001). (E) Immunofluorescence of sections from the proximal descending thoracic aorta of vEDS Map2k6+/+ and vEDS Map2k6–/– mice. The dashed line marks the approximate boundaries of the aortic wall. Scale bar is 50 microns. (F) Mean and total protein phosphatase 1 (PP1) dephosphorylation activity in aortic protein lysates from 129 vEDS Map2k6+/+ mice (n = 6) and 129 vEDS Map2k6–/– (n = 7). P value refers to unpaired t test with Welch’s correction (* P < 0.05, ** P < 0.01).DiFMU, 6,8-difluoro-7-hydroxy-4-methylcoumarin. In D and F, each symbol represents an independent biological replicate, with unfilled symbols representing male samples. Error bars show mean ± SEM. (G) Kaplan-Meier survival curve comparing control 129 vEDS Map2k6–/– mice (n = 33, 17 females and 16 males) with 129 vEDS Map2k6–/– (n = 11, 8 females and 3 males) mice receiving ruboxistaurin (PKC inhibitor) starting at postnatal day 21. Significant differences were calculated using log-rank (Mantel-Cox) analysis (* P < 0.05).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts